Autoimmune Myocarditis

L.E.A.P.S. Technology Shows Protection In Animal Model

Published in Vaccine Weekly, February 6th, 2002

Dr. Daniel Zimmerman, CEL-SCI Corporation presented evidence at the SMi "Anti-Inflammatory Therapeutics" Conference in London, U.K., that administration of a proprietary peptide based on CEL-SCI's L.E.A.P.S. technology has prevented the development of, and lessened the severity of the inflammation associated with experimental autoimmune myocarditis in mice.

Autoimmune myocarditis, an autoimmune disease affecting the heart muscle, is caused by an attack on the patient's heart muscle by his/her own immune cells and antibodies. Myocarditis is a precursor to dilated cardiomyopathy which is an end stage cardiac disease usually requiring a heart transplant. The incidence of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-02-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry